In order to confirm the ability of cholesterol or mevalonate to induce the activation of the ERRα pathway in breast cancer cells, we monitored the ERRα expression levels in cholesterol/mevalonate-treated cells in the presence of XCT790, which is a well-known selective ERRα inhibitor. The gene discussed is ESRRA; the disease is breast cancer.